Selected Safety Information
- Hormonal contraceptives may affect the metabolism of other drugs. Consequently, plasma concentrations may either increase (for example, cyclosporin) or decrease (for example, lamotrigine).
- Rule out pregnancy before inserting NEXPLANON.
NEXPLANON: At-a-glance
NEXPLANON is a contraceptive with efficacy that doesn’t completely rely on her. Consider the following information when counselling appropriate patients about NEXPLANON.
Reliable
>99% effective with just 1 insertion - with less than 1 pregnancy per 100 women who use NEXPLANON for one year
No self-administration required
Efficacy is achieved through the implant’s continuous release of etonogestrel over 3 years
Reversible
fertility has been shown to return quickly after removal
In clinical trials of non-radiopaque etonogestrel implant (IMPLANON), pregnancies occurred as early as 7 to 14 days after removal
A patient should restart contraception immediately after removal of NEXPLANON if continued contraceptive protection is desired
Failure to remove the implant may result in continued effects of etonogestrel, such as compromised fertility, ectopic pregnancy, or persistence or occurrence of a drug-related adverse event
Convenient
1 insertion for up to 3 years
Does not depend on daily, weekly, monthly, or quarterly administration
NEXPLANON must be removed by the end of the third year and may be replaced by a new NEXPLANON at the time of removal, if continued contraceptive protection is desired
Discreet
1 flexible NEXPLANON just under her skin
A single NEXPLANON inserted in a discreet location in the inner side of the upper arm
A soft and flexible implant
Small in size (4 cm in length, 2 mm in diameter), so no one has to know it is there but you and her
Selected Safety Information
About NEXPLANON (etonogestrel implant) 68 mg (continued)
- Based on limited clinical data, NEXPLANON may be used during breastfeeding after the fourth postpartum week. Use of NEXPLANON before the fourth postpartum week has not been studied. Small amounts of etonogestrel are excreted in breast milk. The health of breast-fed infants whose mothers began using the non-radiopaque etonogestrel implant during the fourth to eighth week postpartum (n=38) was evaluated in a comparative study with infants of mothers using a non-hormonal IUD (n=33). They were breast-fed for a mean duration of 14 months and followed up to 36 months of age. No significant effects and no differences between the groups were observed on the physical and psychomotor development of these infants. No differences between groups in the production or quality of breast milk were detected.
- Safety and efficacy of NEXPLANON have been established in women of reproductive age and are expected to be the same for postpubertal adolescents. However, no studies have been conducted in women less than 18 years of age. Use of this product before menarche is not indicated.
- The efficacy of NEXPLANON in women who weighed more than 130% of their ideal body weight has not been defined because such women were not studied in clinical trials. Serum concentrations of etonogestrel are inversely related to body weight and decrease with time after implant insertion. Therefore, NEXPLANON may be less effective in overweight women.
- NEXPLANON does not protect against HIV (AIDS) or other sexually transmitted diseases.
